Benitec Biopharma Inc. (BNTC)
Benitec Biopharma Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Hayward, CA, US. The stock last traded at $9.59, down 0.52% on the session, giving a market capitalisation of $329.5M. On trailing twelve-month figures it carries a trailing P/E of -9.79, a net margin of 0.0%. Its beta of 0.27 implies it has historically moved less than the broad market.
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Benitec Biopharma Inc. is most often compared with the following Healthcare names: